I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative T-cell engagers and monoclonal antibodies for the treatment of cancer and autoimmune diseases
The company leverages its proprietary technology platform to create therapies that target specific biological pathways, aiming to address unmet medical needs in oncology. With a strong emphasis on research and collaboration, I-Mab works to bring advanced therapies to patients worldwide, enhancing treatment options and outcomes in the field of medicine.
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259 million to complete development of its product.
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent BioPharma.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with potential value of more than $1 billion.
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals.
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet will receive an initial payment of $11.5 million.
Wall Street bonuses fell 26% last year. This was the biggest drop since 2008. Wall Street is estimated to be responsible for 16% of all economic activity in NYC. Wild nights out for ibankers slowing down?
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the fourth quarter Eli Lilly ranks as the company’s biggest institutional investor after six rounds of financing
